BioVersys Reports Positive Results from AlpE Tuberculosis Trial
News related to:BioVersys AG · 2 min read
BASEL, Switzerland, Nov. 20, 2026 /CourierPR/ -- BioVersys AG, a biopharmaceutical company focused on developing novel antibacterial products, has announced positive results from a Phase 2a clinical trial evaluating its compound Alpibectir (AlpE) in combination with ethionamide for the treatment of drug-sensitive pulmonary tuberculosis. The study, known as ENABLE (NCT06748937), evaluated the efficacy and safety of a 45 mg dose of alpibectir in combination with 125 mg or 250 mg of ethionamide, replacing isoniazid in the standard-of-care regimen HRZE.
The trial, conducted by TASK as part of the European Union Innovative Health Initiative Joint Undertaking (EU IHI JU) project UNITE4TB, involved 14 days of treatment and showed that all regimens evaluated achieved early bactericidal activity. The regimen containing 250 mg of ethionamide demonstrated more activity than the regimen with 125 mg, indicating that AlpE could potentially replace isoniazid in the treatment of isoniazid-resistant tuberculosis. AlpE was generally well-tolerated and showed an acceptable safety profile over the 14-day trial period.
The ENABLE study was presented at the Union World Conference on Lung Health, which took place from November 17 to 20, 2026, in Rio de Janeiro, Brazil. The conference also featured presentations on the further development of AlpE-containing regimens and clinical data from an earlier Phase 2a study.
A separate Phase 2b clinical trial, STEP2C, is currently evaluating the activity of AlpE-RZE during the first two months of treatment. This trial, conducted through UNITE4TB and supported by GSK and BioVersys, is being carried out in six African countries under the European Union's IMI2 UNITE4TB project, with the Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, as the trial sponsor.
Alpibectir, previously known as BVL-GSK098, is a small molecule developed from BioVersys' TRIC platform in collaboration with GSK, the Institut Pasteur Lille, and the University of Lille. Alpibectir acts through a novel mode of action, potentiating the activity of the anti-TB drug ethionamide (Eto). AlpE, the combination of alpibectir and ethionamide, is being studied for its potential to lower the efficacious human dose of Eto, minimize dose-dependent side effects, and overcome Eto resistance. In 2023, AlpE was granted orphan-drug designation (ODD) for the treatment of tuberculosis by the U.S. Food and Drug Administration, providing seven years of market exclusivity. Similarly, in 2025, AlpE was granted Orphan Designation from the European Medicines Agency, providing 10-year market exclusivity.
The UNITE4TB project, one of nine projects within the AMR Accelerator, is working across a global clinical trials network to accelerate the clinical evaluation of novel drugs and drug combinations for tuberculosis. The project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007873. The JU receives support from the European Union's Horizon 2020 research and innovation programme and from EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute 50% of the funding, while the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.